In addition, it showed a cardiac impact by reducing ventricular fibrosis; increasing the expression of Cav1.2, Kv4.2, Nav1.5, and Cx43; and reducing the expression of CaMKII, p-CaMKII, p-RyR2 (S2808), and p-RyR2 (S2814) in the left ventricle. The gene discussed is RYR2; the disease is fibrosis.